Monika M. S.
- Country
- Poland
- Department
- Klin.Transplantacji Szpiku Onkologii i Hemat. Dziecięcej
Research Overview
- Phase II Randomized Study of Bortezomib with Dexamethasone, Mitoxantrone, Vincristine, Pegaspargase, and Methotrexate in High-Risk Relapsed Pediatric ALL
- Phase 2 Randomized Study of Inotuzumab Ozogamicin Monotherapy Versus ALLR3 Regimen in Pediatric High-Risk First Relapse CD22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Data & Insights
Has run more than one trial at 36 of 137 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating acute lymphoblastic leukemia (ALL), with particular emphasis on high-risk cases and relapsed conditions in pediatric patients.
- Childhood ALL Treatment
- High-Risk Leukemia Management
- Relapsed ALL Therapy
Clinical expertise extends to innovative therapeutic approaches for B-cell precursor acute lymphoblastic leukemia in young patients aged 1 to 18 years.
Pediatric Oncology
Focus areas include developing treatment strategies for childhood hematologic malignancies, specifically targeting high-risk patient populations.
- Pediatric Cancer Care
- Advanced Treatment Protocols
- Targeted Therapy Applications
The investigator works with novel therapeutic agents in treating resistant and recurrent forms of pediatric leukemia.
Therapeutic Innovation
Expertise in evaluating targeted immunotherapy approaches for treating aggressive forms of childhood leukemia.
- Novel Treatment Strategies
- Immunotherapeutic Applications
- Treatment Response Assessment
Special interest in developing therapeutic protocols for CD22-positive leukemia variants.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.